1887

Chapter 28 : Public Health Considerations for the Use of Cholera Vaccines in Cholera Control Programs

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Public Health Considerations for the Use of Cholera Vaccines in Cholera Control Programs, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818364/9781555810672_Chap28-1.gif /docserver/preview/fulltext/10.1128/9781555818364/9781555810672_Chap28-2.gif

Abstract:

Conventional parenteral cholera vaccines have largely been abandoned as public health tools, and recent studies have elucidated the probable reason for their poor performance. This chapter reviews the reasons that older parenteral cholera vaccines have largely been abandoned as public health tools. It also discusses several considerations that should be addressed when judging whether new cholera vaccines are sufficiently attractive to be used in public health programs. The chapter focuses to the use of cholera vaccines in populations residing in areas affected by cholera and do not specifically consider the problem of vaccinating travelers to such areas. In developing countries, cholera may occur in either epidemic or endemic form. A basic requirement for making a rational decision to launch a cholera vaccine program is that the burden of cholera morbidity and mortality be sufficient to warrant the diversion of scarce resources necessary for such a program. Several protective characteristics of a cholera vaccine must be considered when its potential utility in public health programs is evaluated. Heterogeneity of vaccine protection, which depends on characteristics of the host and of the infecting vibrio, must also be contemplated, though again, the importance of such heterogeneity will vary with the epidemiologic setting for vaccination. The formulation of a vaccine may have an important influence on cultural acceptability.

Citation: Clemens J, Spriggs D, Sack D. 1994. Public Health Considerations for the Use of Cholera Vaccines in Cholera Control Programs, p 425-440. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch28

Key Concept Ranking

Yellow Fever Vaccine
0.4320439
Cholera Vaccine
0.41921026
0.4320439
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818364.chap28
1. Akesode, E. 1982. Factors affecting the use of primary health care clinics for children. J. Epidemiol. Commun. Health 36:310314.
2. Azurin, J.,, and M. Alverin. 1974. Field evaluation of environmental sanitation measures against cholera. Bull. W.H.O. 51:1926.
3. Bart, K.,, Z. Huq,, M. Khan,, and W. H. Mosley. 1970. Seroepidemiological studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J. Infect. Dis. 121:S17S24.
4. Benenson, A. 1976. Review of experience with whole-cell and somatic antigen vaccines, p. 228252. In Symposium on Cholera, U.S.-Japan Cooperative Medical Science Program. Sapporo, Japan.
5. Bennish, M.,, A. Azad,, O. Rahman,, and R. Phillips. 1990. Hypoglycemia during diarrhea in childhood: prevalence, pathophysiology, and outcome. N. Engl. J. Med. 322:13571363.
6. Bhatnagar, R.,, K. West,, S. Vitale,, and A. Sommer. 1991. Risk of cataract and history of severe diarrheal disease in southern India. Arch. Ophthalmol. 109:696699.
7. Burt, R. 1973. Differential impact of social integration on participation in the diffusion of innovations. Soc. Sci. Res. 2:120.
8. Carpenter, C. C. J. 1976. Treatment of cholera-tradition and authority versus science, reason, and humanity. Johns Hopkins Med. J. 139:153162.
9. Clemens, J., 1990. Assessing the value of enteric vaccines: efficacy, effectiveness, and efficiency, p. 131140. In D. Sack, and L. Freij (ed.), Prospects for Public Health Benefits in Developing Countries from New Vaccines against Enteric Infections. SAREC Documentation, Conference Report 2. Gotab, Stockholm.
10. Clemens, J.,, D. Sack,, J. Harris,, J. Chakraborty,, M. R. Khan,, S. Huda,, E. Ahmed,, J. Gomes,, M. Rao,, A.-M. Svennerholm,, and J. Holmgren. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis. 159:770773.
11. Clemens, J.,, D. Sack,, J. Harris,, J. Chakraborty,, R. Neogy,, B. Stanton,, N. Huda,, M. U. Khan,, B. A. Kay,, M. R. Khan,, M. Ansaruzzaman,, M. Yunus,, M. R. Rao,, A.-M. Svennerholm,, and J. Holmgren. 1988. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxinproducing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158: 372379.
12. Clemens, J.,, D. Sack,, J. Harris,, M. R. Khan,, J. Chakraborty,, S. Chowdhury,, M. R. Rao,, F. P. L. van Loon,, B. Stanton,, M. Yunus,, M. Ali,, M. Ansaruzzaman,, A.-M. Svennerholm,, and J. Holmgren. 1990. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am. J. Epidemiol. 131:400411.
13. Clemens, J.,, D. A. Sack,, J. Harris,, F. van Loon,, J. Chakraborty,, F. Ahmed,, M. R. Rao,, M. R. Khan,, M. Yunus,, N. Huda,, B. Stanton,, B. Kay,, S. Walter,, R. Eeckels,, A.-M. Svennerholm,, and J. Holmgren. 1990. Field trial of oral cholera vaccines in Bangladesh: results from long-term follow-up. Lancet 335:270273.
14. Clemens, J. D.,, D. Sack,, J. R. Harris,, J. Chakraborty,, M. R. Khan,, B. Stanton,, M. Ali,, F. Ahmed,, M. Yunus,, B. Kay,, M. U. Khan,, M. R. Rao,, A.-M. Svennerholm,, and J. Holmgren. 1988. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet 2:13751378.
15. Clemens, J. D.,, D. A. Sack,, M. R. Rao,, J. Chakraborty,, M. R. Khan,, B. Kay,, F. Ahmed,, A. K. Banik,, F. P. L. van Loon,, M. Yunus,, and J. R. Harris. 1992. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J. Infect. Dis. 166:10291034.
16. Clemens, J. D.,, F. P. L. van Loon,, M. Rao,, D. A. Sack,, F. Ahmed,, J. Chakraborty,, M. R. Khan,, M. Yunus,, J. R. Harris,, A.-M. Svennerholm,, and J. Holmgren. 1992. Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am. J. Epidemiol. 135:865874.
17. Creese, A.,, N. Sriyabayya,, G. Casabal,, and G. Wiseso. 1982. Cost-effectiveness appraisal of immunization programmes. Bull. W.H.O. 60:621632.
18. Cvjetanovic, B.,, B. Grab,, and K. Uemura. 1978. Dynamics of acute bacterial diseases. Bull. W.H.O. 56(Suppl l):6580.
19. Deb, B.,, B. Sircar,, P. Senoupta,, S. De,, S. Mondal,, D. Gupta,, N. Saha,, S. Ghosh,, U. Mitra,, and S. Pal. 1986. Studies on interventions to prevent El Tor cholera transmission in urban slums. Bull. W.H.O. 64:127131.
20. de Zoysa, L.,, and R. Feachem. 1985. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull. W.H.O. 63:569583.
21. Dick, B. 1985. Issues in immunization in developing countries—an overview. EPC publication 7. London School of Hygiene and Tropical Medicine, London.
22. Esrey, S.,, J. Potash,, L. Roberts,, and C. Sniff. 1990. Health benefits from improvements in water supply and sanitation: survey and analysis of the literature on selected diseases. WASH technical report 66. Water and Sanitation for Health Project.
23. Felsenfield, O.,, R. H. Wold,, and K. Gyr. 1973. Simultaneous vaccination against cholera and yellow fever. Lancet 1:457458.
24. Glass, R.,, S. Becker,, M. Huq,, B. Stoll,, M. U. Khan,, M. Merson,, J. Lee,, and R. Black. 1982. Endemic cholera in rural Bangladesh, 1966-1980. Am. J. Epidemiol. 116:959970.
25. Glass, R.,, and R. Black,. 1992. The epidemiology of cholera, p. 129154. In D. Barua, and W. Greenough (ed.), Cholera. Plenum Press, New York.
26. Glass, R.,, M. Claeson,, P. Blake,, R. Waldman,, and N. Pierce. 1991. Cholera in Africa: lessons on transmission and control for Latin America. Lancet 338:791795.
27. Glass, R.,, A.-M. Svennerholm,, B. Stoll,, M. R. Khan,, K. Hossain,, M. Huq,, and J. Holmgren. 1983. Protection against cholera in breast-fed children by antibodies in breast milk. N. Engl. J. Med. 308:13891392.
28. Heggenhougen, K., 1990. The concept of acceptability: the role of communication and the social sciences, p. 180189. In D. Sack, and L. Freij (ed.), Prospects for Public Health Benefits in Developing Countries from New Vaccines against Enteric Infections. SAREC Documentation, Conference Report 2. Gotab, Stockholm.
29. Hernborg, A. 1985. Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 2:10721013.
30. Hirschhorn, N.,, A. Chaudhury,, and J. Lindenbaum. 1969. Cholera in pregnant women. Lancet 1:12301232.
31. Hirschhorn, N.,, J. Lindenbaum,, W. Greenough,, and S. Alam. 1966. Hypoglycemia in children with acute diarrhea. Lancet 2:128132.
32. Holmgren, J.,, and A.-M. Svennerholm. 1983. Cholera and the immune response. Prog. Allergy 33:106119.
33. Hughes, J.,, J. Boyce,, R. Levine,, M. Khan,, K. Aziz,, M. Huq,, and G. Curlin. 1982. Epidemiology of El Tor cholera in rural Bangladesh: importance of surface water in transmission. Bull. W.H.O. 60:395404.
34. Huq, A.,, E. Small,, P. West,, M. Huq,, and R. Colwell. 1983. Ecological relationships between Vibrio cholerae and planktonic crustacean copepods. Appl. Environ. Microbiol. 45:275283.
35. Johnston, J.,, D. Martin,, J. Perdue,, L. McFarland,, C. Caraway,, E. Lippy,, and P. Blake. 1983. Cholera on a Gulf Coast oil rig. N. Engl. J. Med. 309:523526.
36. Levine, R.,, M. R. Khan,, S. D'Souza,, and D. Nalin. 1976. Failure of sanitary wells to protect against cholera and other diarrheas in Bangladesh. Lancet 2:8689.
37. Mandara, M.,, and F. Mhalu. 1980. Cholera control in an inaccessible district in Tanzania: importance of temporary rural centers. Med. J. Zambia 15:1013.
38. McCormack, W.,, A. Chowdhury,, N. Jahangir,, A. Ahmed,, and W. H. Mosley. 1968. Tetracycline prophylaxis in families of cholera patients. Bull. W.H.O. 38:787797.
39. Mosley, W. H.,, K. M. A. Aziz,, A. S. M. Rahman,, A. K. Chowdhury,, A. Ahmed,, and M. Fahimuddin. 1972. Report of the 1966-67 cholera vaccine trial in rural East Pakistan. Bull. W.H.O. 47:229238.
40. Nokes, D.,, and R. Anderson. 1988. The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes. Epidemiol. Infect. 101: 120.
41. Patriarca, P.,, P. Wright,, and T. J. John. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: a review. Rev. Infect. Dis. 13:926939.
42. PoDitzer, R. 1959. Cholera. World Health Organization, Geneva.
43. Ries, A.,, D. J. Vugia,, L. Beingolea,, A. Palacios,, E. Vasquez,, J. Wells,, N. Garcia Baca,, D. Swerdlow,, M. Pollack,, and N. Bean. 1992. Cholera in Piura, Peru: a modern urban epidemic. J. Infect. Dis. 166:14291433.
44. Sack, D., 1990. Cost effectiveness model for cholera vaccination with oral vaccines, p. 8289. In D. Sack, and L. Freij (ed.), Prospects for Public Health Benefits in Developing Countries from New Vaccines against Enteric Infections. SAREC Documentation, Conference Report 2. Gotab, Stockholm.
45. Shahid, N.,, A. Samadi,, M. Khan,, and M. Huq. 1984. Classical vs. El Tor cholera. A prospective family study of a concurrent outbreak. J. Diarrhoeal Dis. Res. 2:73.
46. Siddique, A. K.,, K. Zaman,, A. Baqui,, K. Akram,, P. Mutsuddy,, A. Eusof,, K. Haider,, S. Islam,, and R. Sack. 1992. Cholera epidemics in Bangladesh: 1985-1991. J. Diarhoeal Dis. Res. 10:7986.
47. Sommer, A. 1972. Ineffectiveness of cholera vaccination as an epidemic control measure. Lancet 1:12321235.
48. Sommer, A.,, and W. Woodward. 1972. The influence of protected water supplies on the spread of classical/Inaba and El Tor Ogawa in rural East Bengal. Lancet 2:985987.
49. Spira, W.,, M. Khan,, Y. Saeed,, and M. Sattar. 1980. Microbiological surveillance of intra-neighborhood El Tor cholera transmission in rural Bangladesh. Bull. W.H.O. 58:731740.
50. Stanton, B.,, M. Rowland,, and J. Clemens. 1987. Oral rehydration solution—too little or too much? Lancet 1:3334.
51. Suharyono,, C. Simanjuntak,, N. Witham,, N. Punjabi,, D. Heppner,, G. Losonsky,, H. Totosudirjo,, A. Rifai,, J. Clemens,, Y. Lim,, D. Burr,, S. Wasserman,, J. Kaper,, K. Sorenson,, S. Cryz,, and M. Levine. 1992. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9 year-old Indonesian children. Lancet 340:689694.
52. Tauxe, R. V.,, and R. A. Blake. 1992. Epidemic cholera in Latin America. JAMA 267:13881390.
53. Weinstein, M. 1981. Economic assessments of medical practices and technologies. Med. Decision Making 1:309330.
54. World Health Organization. 1974. International Health Regulations, 2nd annotated ed. World Health Organization, Geneva.
55. World Health Organization. 1986. Guidelines for Cholera Control. WHO/CDD/SER 80.4 Rev. 1. World Health Organization, Geneva.
56. World Health Organization. 1992. Guidelines for Cholera Control (rev. 1992). WHO/CDD/ SER 80.4 Rev. 3. World Health Organization, Geneva.

Tables

Generic image for table
Table 1

Issues to consider in making decisions to use cholera vaccine in public health programs

Citation: Clemens J, Spriggs D, Sack D. 1994. Public Health Considerations for the Use of Cholera Vaccines in Cholera Control Programs, p 425-440. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch28
Generic image for table
Table 2

Epidemiologic setting for vaccination: epidemic versus endemic cholera

Citation: Clemens J, Spriggs D, Sack D. 1994. Public Health Considerations for the Use of Cholera Vaccines in Cholera Control Programs, p 425-440. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch28
Generic image for table
Table 3

Protective characteristics relevant to use of cholera vaccines in public health programs

Citation: Clemens J, Spriggs D, Sack D. 1994. Public Health Considerations for the Use of Cholera Vaccines in Cholera Control Programs, p 425-440. In Wachsmuth I, Blake P, Olsvik Ø (ed), and Cholera. ASM Press, Washington, DC. doi: 10.1128/9781555818364.ch28

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error